{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CD40+Deficiency", "query": { "condition": "CD40 Deficiency" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T09:48:17.504Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06665646", "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CD40.HIVRI.Env (VRIPRO)", "type": "BIOLOGICAL" }, { "name": "Hiltonol Poly-ICLC-adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": "2025-09-14", "completion_date": "2027-05-04", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 7, "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06665646" }, { "nct_id": "NCT00001145", "title": "Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunoproliferative Disorder" ], "interventions": [ { "name": "Bacteriophage", "type": "DRUG" }, { "name": "rhuCD40L", "type": "DRUG" }, { "name": "KLH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "1999-10", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001145" }, { "nct_id": "NCT03333486", "title": "Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Leukemia in Remission", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia With FLT3/ITD Mutation", "Acute Myeloid Leukemia With Gene Mutations", "Aplastic Anemia", "B-Cell Non-Hodgkin Lymphoma", "CD40 Ligand Deficiency", "Chronic Granulomatous Disease", "Chronic Leukemia in Remission", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Congenital Amegakaryocytic Thrombocytopenia", "Congenital Neutropenia", "Congenital Pure Red Cell Aplasia", "Glanzmann Thrombasthenia", "Immunodeficiency Syndrome", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Plasma Cell Myeloma", "Polycythemia Vera", "Recurrent Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Severe Aplastic Anemia", "Shwachman-Diamond Syndrome", "Sickle Cell Disease", "T-Cell Non-Hodgkin Lymphoma", "Thalassemia", "Waldenstrom Macroglobulinemia", "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 31, "start_date": "2017-12-07", "completion_date": "2023-08-28", "has_results": true, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333486" }, { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT01652092", "title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "SCID", "Omenn's Syndrome", "Reticular Dysgenesis", "Wiskott-Aldrich Syndrome", "Bare Lymphocyte Syndrome", "Common Variable Immunodeficiency", "Chronic Granulomatous Disease", "CD40 Ligand Deficiency", "Hyper IgM Syndrome", "X-linked Lymphoproliferative Disease", "Hemophagocytic Lymphohistiocytosis", "Griscelli Syndrome", "Chediak-Higashi Syndrome", "Langerhan's Cell Histiocytosis" ], "interventions": [ { "name": "Alemtuzumab 0.3 mg", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "BIOLOGICAL" }, { "name": "Fludarabine phosphate 40 mg", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Alemtuzumab 0.2 mg", "type": "DRUG" }, { "name": "Fludarabine phosphate 30 mg", "type": "DRUG" }, { "name": "MESNA", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 57, "start_date": "2012-09-04", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652092" }, { "nct_id": "NCT07284641", "title": "Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Common Variable Immunodeficiency (CVID)", "Primary Immune Regulatory Disorder", "Immune Dysregulation", "DiGeorge Syndrome", "STAT 1 Gain of Function", "STAT 3 Gain of Function", "Hypomorphic RAG1 Deficiency", "CD40 Ligand Deficiency", "Mendelian Susceptibility to Mycobacterial Disease", "GATA2 Associated Immunodeficiency", "CD40 Deficiency", "Hypomorphic RAG2 Deficiency", "Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome", "Omenn Syndrome", "Chronic Granulomatous Disease" ], "interventions": [ { "name": "Hematopoietic stem cell transplant (HSCT)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "5 Years to 40 Years" }, "enrollment_count": 25, "start_date": "2026-05-04", "completion_date": "2031-02-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284641" }, { "nct_id": "NCT00266513", "title": "Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hyper-IgM Syndrome", "Ectodermal Dysplasia" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 119, "start_date": "2005-12-14", "completion_date": "2013-07-11", "has_results": false, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00266513" }, { "nct_id": "NCT00730314", "title": "Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Thalassemia", "Anemia", "Granuloma", "Wiskott-Aldrich Syndrome", "Chediak Higashi Syndrome", "Osteopetrosis", "Neutropenia", "Thrombocytopenia", "Hurler Disease", "Niemann-Pick Disease", "Fucosidosis" ], "interventions": [ { "name": "Hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 25, "start_date": "2008-08", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2016-06-23", "last_synced_at": "2026-06-26T09:48:17.504Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00730314" } ] }